{"id":11065,"date":"2025-07-12T12:23:00","date_gmt":"2025-07-12T10:23:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=11065"},"modified":"2025-08-08T12:30:10","modified_gmt":"2025-08-08T10:30:10","slug":"geteccu-position-paper-on-fragility-advanced-age-and-inflammatory-bowel-disease","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/geteccu-position-paper-on-fragility-advanced-age-and-inflammatory-bowel-disease\/","title":{"rendered":"GETECCU position paper on fragility, advanced age and inflammatory bowel disease."},"content":{"rendered":"
\n

Documento de posicionamiento de geteccu sobre fragilidad, edad avanzada y enfermedad inflamatoria intestinal<\/p>\n<\/div>\n\n

\n

M\u00edriam\u00a0Ma\u00f1osa\u00a0a<\/sup>,\u00a0Margalida\u00a0Calafat\u00a0a<\/sup>,\u00a0Esther\u00a0Francia\u00a0b<\/sup>,\u00a0Francesc\u00a0Riba\u00a0c<\/sup>,\u00a0Francisco\u00a0Mesonero\u00a0d<\/sup>,\u00a0Cristina\u00a0Su\u00e1rez\u00a0e<\/sup>,\u00a0Santiago\u00a0Garc\u00eda-L\u00f3pez\u00a0f<\/sup>,\u00a0Francisco\u00a0Losfablos\u00a0g<\/sup>,\u00a0Xavier\u00a0Calvet\u00a0hi<\/sup>,\u00a0Eugeni\u00a0Dom\u00e8nech\u00a0ai<\/sup>,\u00a0Ana\u00a0Guti\u00e9rrez Casbas\u00a0j<\/sup>,\u00a0Ingrid\u00a0Ord\u00e1s\u00a0k<\/sup>,\u00a0Luis\u00a0Mench\u00e9n\u00a0l<\/sup>,\u00a0Francisco\u00a0Rodr\u00edguez-Moranta\u00a0m<\/sup>,\u00a0Yamile\u00a0Zabana\u00a0n<\/sup><\/p>\n<\/div>\n\n

\n

Gastroenterolog\u00eda y Hepatolog\u00eda, 2025, 502529, ISSN 0210-5705, https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502529.<\/p>\n<\/div>\n\n

\n

Resumen<\/h2>\n<\/div>\n\n
\n

La fragilidad es un estado de vulnerabilidad caracterizado por una disminuci\u00f3n de la reserva fisiol\u00f3gica y la capacidad de respuesta ante el estr\u00e9s, lo que aumenta el riesgo de complicaciones, efectos adversos a los tratamientos y al deterioro funcional. La valoraci\u00f3n de la fragilidad permite determinar la edad biol\u00f3gica de los pacientes, m\u00e1s all\u00e1 de su edad cronol\u00f3gica, proporcionando una visi\u00f3n m\u00e1s precisa de su estado de salud y necesidades asistenciales. La proporci\u00f3n de adultos de edad avanzada con EII se halla en aumento de forma paralela al envejecimiento de la poblaci\u00f3n general y se estima que, en la pr\u00f3xima d\u00e9cada, m\u00e1s de un tercio de los pacientes con EII superar\u00e1n los 60 a\u00f1os. Esta poblaci\u00f3n puede sufrir las complicaciones derivadas de la propia EII desarrolladas previamente a la vez que es particularmente susceptible a desarrollar efectos secundarios del tratamiento, lo que hace imprescindible su evaluaci\u00f3n integral con el fin de identificar aquellos m\u00e1s vulnerables. A la fragilidad se unen otros s\u00edndromes geri\u00e1tricos como la comorbilidad y la polifarmacia que pueden interferir de forma notable con el manejo y el curso de la EII, condicionando la estrategia terap\u00e9utica y el pron\u00f3stico.<\/p>\n<\/div>\n\n

\n

Objetivo<\/h3>\n<\/div>\n\n
\n

En este contexto, la evaluaci\u00f3n geri\u00e1trica integral debe ser sistem\u00e1tica en los pacientes de edad avanzada con EII, con el objetivo de detectar d\u00e9ficits funcionales e implementar intervenciones espec\u00edficas de apoyo nutricional, rehabilitaci\u00f3n funcional y atenci\u00f3n psicol\u00f3gica para optimizar su evoluci\u00f3n. Este documento de posicionamiento pretende establecer recomendaciones al respecto basadas en la evidencia disponible.<\/p>\n<\/div>\n\n

\n

Conclusiones<\/h3>\n<\/div>\n\n
\n

La incorporaci\u00f3n sistem\u00e1tica de la valoraci\u00f3n geri\u00e1trica integral en el manejo de personas mayores con EII representa una estrategia esencial para mejorar los resultados cl\u00ednicos, adaptar los tratamientos a la capacidad funcional del paciente y favorecer un enfoque verdaderamente centrado en la persona.<\/p>\n<\/div>\n\n

\n

Recomendamos valorar el uso de GMA en los<\/em>\u00a0pacientes fr\u00e1giles o de edad avanzada con EII corticodependientes por su seguridad.<\/em><\/p>\n<\/div>\n\n

\n

En los pacientes con EII de edad avanzada o en situaci\u00f3n de fragilidad, donde el riesgo de efectos adversos por inmunosupresores y corticoides es mayor, la GMA puede representar una opci\u00f3n terap\u00e9utica segura. Esta estrategia permite controlar la inflamaci\u00f3n sin incrementar significativamente el riesgo de infecciones o neoplasias. Disponemos de datos que han demostrado que la GMA puede inducir remisi\u00f3n cl\u00ednica en un porcentaje considerable de pacientes mayores con CU moderada o grave, con un perfil de seguridad favorable y sin eventos adversos graves, incluso en presencia de m\u00faltiples comorbilidades<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Documento de posicionamiento de geteccu sobre fragilidad, edad avanzada y enfermedad inflamatoria intestinal M\u00edriam\u00a0Ma\u00f1osa\u00a0a,\u00a0Margalida\u00a0Calafat\u00a0a,\u00a0Esther\u00a0Francia\u00a0b,\u00a0Francesc\u00a0Riba\u00a0c,\u00a0Francisco\u00a0Mesonero\u00a0d,\u00a0Cristina\u00a0Su\u00e1rez\u00a0e,\u00a0Santiago\u00a0Garc\u00eda-L\u00f3pez\u00a0f,\u00a0Francisco\u00a0Losfablos\u00a0g,\u00a0Xavier\u00a0Calvet\u00a0hi,\u00a0Eugeni\u00a0Dom\u00e8nech\u00a0ai,\u00a0Ana\u00a0Guti\u00e9rrez Casbas\u00a0j,\u00a0Ingrid\u00a0Ord\u00e1s\u00a0k,\u00a0Luis\u00a0Mench\u00e9n\u00a0l,\u00a0Francisco\u00a0Rodr\u00edguez-Moranta\u00a0m,\u00a0Yamile\u00a0Zabana\u00a0n Gastroenterolog\u00eda y Hepatolog\u00eda, 2025, 502529, ISSN 0210-5705, https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502529. Resumen La fragilidad es un estado de vulnerabilidad caracterizado por una disminuci\u00f3n de la reserva fisiol\u00f3gica y la capacidad de respuesta ante el estr\u00e9s, lo que aumenta el riesgo de complicaciones, efectos […]<\/p>\n","protected":false},"template":"","scientific_tags":[394,159,310,713,424,350,426,886,306],"class_list":["post-11065","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-consensus","scientific_tags-crohns-disease","scientific_tags-elderly","scientific_tags-fragile","scientific_tags-gma","scientific_tags-guidelines","scientific_tags-ibd","scientific_tags-position-paper","scientific_tags-ulcerative-colitis"],"acf":[],"yoast_head":"\nGETECCU position paper on fragility, advanced age and inflammatory bowel disease. - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/geteccu-position-paper-on-fragility-advanced-age-and-inflammatory-bowel-disease\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GETECCU position paper on fragility, advanced age and inflammatory bowel disease. - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Documento de posicionamiento de geteccu sobre fragilidad, edad avanzada y enfermedad inflamatoria intestinal M\u00edriam\u00a0Ma\u00f1osa\u00a0a,\u00a0Margalida\u00a0Calafat\u00a0a,\u00a0Esther\u00a0Francia\u00a0b,\u00a0Francesc\u00a0Riba\u00a0c,\u00a0Francisco\u00a0Mesonero\u00a0d,\u00a0Cristina\u00a0Su\u00e1rez\u00a0e,\u00a0Santiago\u00a0Garc\u00eda-L\u00f3pez\u00a0f,\u00a0Francisco\u00a0Losfablos\u00a0g,\u00a0Xavier\u00a0Calvet\u00a0hi,\u00a0Eugeni\u00a0Dom\u00e8nech\u00a0ai,\u00a0Ana\u00a0Guti\u00e9rrez Casbas\u00a0j,\u00a0Ingrid\u00a0Ord\u00e1s\u00a0k,\u00a0Luis\u00a0Mench\u00e9n\u00a0l,\u00a0Francisco\u00a0Rodr\u00edguez-Moranta\u00a0m,\u00a0Yamile\u00a0Zabana\u00a0n Gastroenterolog\u00eda y Hepatolog\u00eda, 2025, 502529, ISSN 0210-5705, https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502529. Resumen La fragilidad es un estado de vulnerabilidad caracterizado por una disminuci\u00f3n de la reserva fisiol\u00f3gica y la capacidad de respuesta ante el estr\u00e9s, lo que aumenta el riesgo de complicaciones, efectos […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/geteccu-position-paper-on-fragility-advanced-age-and-inflammatory-bowel-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-08T10:30:10+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/geteccu-position-paper-on-fragility-advanced-age-and-inflammatory-bowel-disease\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/geteccu-position-paper-on-fragility-advanced-age-and-inflammatory-bowel-disease\/\",\"name\":\"GETECCU position paper on fragility, advanced age and inflammatory bowel disease. - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2025-07-12T10:23:00+00:00\",\"dateModified\":\"2025-08-08T10:30:10+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/geteccu-position-paper-on-fragility-advanced-age-and-inflammatory-bowel-disease\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GETECCU position paper on fragility, advanced age and inflammatory bowel disease. - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/geteccu-position-paper-on-fragility-advanced-age-and-inflammatory-bowel-disease\/","og_locale":"es_ES","og_type":"article","og_title":"GETECCU position paper on fragility, advanced age and inflammatory bowel disease. - Adacyte","og_description":"Documento de posicionamiento de geteccu sobre fragilidad, edad avanzada y enfermedad inflamatoria intestinal M\u00edriam\u00a0Ma\u00f1osa\u00a0a,\u00a0Margalida\u00a0Calafat\u00a0a,\u00a0Esther\u00a0Francia\u00a0b,\u00a0Francesc\u00a0Riba\u00a0c,\u00a0Francisco\u00a0Mesonero\u00a0d,\u00a0Cristina\u00a0Su\u00e1rez\u00a0e,\u00a0Santiago\u00a0Garc\u00eda-L\u00f3pez\u00a0f,\u00a0Francisco\u00a0Losfablos\u00a0g,\u00a0Xavier\u00a0Calvet\u00a0hi,\u00a0Eugeni\u00a0Dom\u00e8nech\u00a0ai,\u00a0Ana\u00a0Guti\u00e9rrez Casbas\u00a0j,\u00a0Ingrid\u00a0Ord\u00e1s\u00a0k,\u00a0Luis\u00a0Mench\u00e9n\u00a0l,\u00a0Francisco\u00a0Rodr\u00edguez-Moranta\u00a0m,\u00a0Yamile\u00a0Zabana\u00a0n Gastroenterolog\u00eda y Hepatolog\u00eda, 2025, 502529, ISSN 0210-5705, https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502529. Resumen La fragilidad es un estado de vulnerabilidad caracterizado por una disminuci\u00f3n de la reserva fisiol\u00f3gica y la capacidad de respuesta ante el estr\u00e9s, lo que aumenta el riesgo de complicaciones, efectos […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/geteccu-position-paper-on-fragility-advanced-age-and-inflammatory-bowel-disease\/","og_site_name":"Adacyte","article_modified_time":"2025-08-08T10:30:10+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/geteccu-position-paper-on-fragility-advanced-age-and-inflammatory-bowel-disease\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/geteccu-position-paper-on-fragility-advanced-age-and-inflammatory-bowel-disease\/","name":"GETECCU position paper on fragility, advanced age and inflammatory bowel disease. - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2025-07-12T10:23:00+00:00","dateModified":"2025-08-08T10:30:10+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/geteccu-position-paper-on-fragility-advanced-age-and-inflammatory-bowel-disease\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/11065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=11065"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=11065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}